Leap Therapeutics (LPTX) 10-Q 2024 Q1 Quarterly report

Exhibit 10.1

FOURTH AMENDMENT TO LEASE

This is a Fourth Amendment to Lease dated as of January 3, 2024 by and between Bulfinch Square Limited Partnership, a Massachusetts limited partnership (“Landlord”) and Leap Therapeutics, Inc., a Delaware corporation (“Tenant”).

WHEREAS, Landlord and Tenant entered into a Lease dated November 13, 2018, as amended by First Amendment to Lease dated August 17, 2021, Second Amendment to Lease dated as of October 1, 202, and Third Amendment to Lease dated as of May 16, 2022 (as so amended, the “Lease”) with respect to certain premises at 47 Thorndike Street, Cambridge, Massachusetts; and

WHEREAS, Tenant wishes to extend the term of the Lease until July 31, 2025 from its current expiration of July 31, 2024; and

NOW, THEREFORE, in consideration of the foregoing, Landlord and Tenant agree as follows:

1.Capitalized terms used herein without definition, including in the foregoing recitals, shall have the meanings ascribed to them by the Lease.

2.The Original Term shall be extended to expire on July 31, 2025. Tenant acknowledges that it has no right to extend the term of the Lease beyond July 31, 2025.

3.Annual Fixed Rent for the period from August 1, 2024 through July 31, 2025 shall be $467,687.00 per annum (i.e. $38,973.92 for each month).

4.Tenant warrants and represents that it has dealt with no broker in connection with this Fourth Amendment to Lease, and that in the event of any brokerage claims or liens against Landlord or the Property predicated on dealings with Tenant, Tenant agrees to defend the same and to indemnify and hold Landlord harmless from any such claim and to discharge any such lien.

5.Except as herein amended the Lease is ratified and affirmed.

-2-

IN WITNESS WHEREOF, Landlord and Tenant have executed this Fourth Amendment to Lease as of the date first set forth above.

LANDLORD:
Bulfinch Square Limited Partnership
By:	Courthouse Associates, Inc., its general partner
	By:
		Kenneth Krozy
		Vice President

TENANT:
Leap Therapeutics, Inc.
By:
	Name: Douglas E. Onsi
	Title: President & CEO